Novel antibodies inhibiting c-met dimerization, and uses thereof
AssigneePierre Fabre Mediacment
InventorLiliane GOETSCH
Life of this patent
Estimating the term…
Abstract
The present inventions relates to a process for the selection of anti c-Met antibodies capable to inhibit both ligand-dependent and ligand-independent activation of c-Met. More particularly, said process is based on the inhibition of the c-Met dimerization. In another aspect, the present invention concerns such antibodies and compositions comprising such antibodies for the preparation of a medicament to treat cancer. Diagnosis process and kits are also part of the invention.
Claims56
-128. (canceled)
An isolated anti-cMet antibody comprising:
- a heavy chain comprising complementarity-determining region (CDR) CDR-H1, CDR-H2, and CDR-H3 comprising, respectively, SEQ ID Nos. 7, 8, and 9;
- and
- a light chain comprising CDR-L1, CDR-L2, and CDR-L3 comprising, respectively, SEQ ID Nos. 15, 16, and 17.
An antibody secreted by the hybridoma deposited at the CNCM, Institut Pasteur, Paris, on Jul. 6, 2007, under the number I-3786.
The isolated anti-cMet antibody of claim 147, wherein the antibody inhibits at least 50% of tumoral cell proliferation for at least one tumor type.
The pharmaceutical composition according to claim 31, wherein said cytotoxic agent is a mitotic inhibitor.
An isolated anti-cMet antibody, or cMet-binding fragment thereof, wherein the antibody or fragment thereof binds an epitope on cMet that is recognized by the 223C4 antibody produced by murine hybridoma 1-3786 deposited at the CNCM, Institut Pasteur, Paris, on Jul. 6, 2007, and inhibits both ligand-dependent and ligand-independent activation of c-Met.
Dependencies are inferred from the claim text.